

Daniel W Lin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3417835/publications.pdf>

Version: 2024-02-01

86
papers

4,370
citations

172386

29
h-index

114418

63
g-index

89
all docs

89
docs citations

89
times ranked

7672
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment in the absence of disease reclassification among men on active surveillance for prostate cancer. <i>Cancer</i> , 2022, 128, 269-274.	2.0	3
2	Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging. <i>Journal of Nuclear Medicine</i> , 2022, 63, 59-68.	2.8	61
3	Genetic factors associated with prostate cancer conversion from active surveillance to treatment. <i>Human Genetics and Genomics Advances</i> , 2022, 3, 100070.	1.0	10
4	Active Surveillance: Very Much "Preferred" for Low-Risk Prostate Cancer. <i>Journal of Urology</i> , 2022, 207, 262-264.	0.2	3
5	Evaluating the Outcomes of Active Surveillance in Grade Group 2 Prostate Cancer: Prospective Results from the Canary PASS Cohort. <i>Journal of Urology</i> , 2022, 207, 805-813.	0.2	3
6	Paracrine Wnt signaling is necessary for prostate epithelial proliferation. <i>Prostate</i> , 2022, 82, 517-530.	1.2	8
7	Considerations on Integrating Prostate-Specific Membrane Antigen Positron Emission Tomography Imaging Into Clinical Prostate Cancer Trials by National Clinical Trials Network Cooperative Groups. <i>Journal of Clinical Oncology</i> , 2022, 40, 1500-1505.	0.8	16
8	Association Between a 22-feature Genomic Classifier and Biopsy Gleason Upgrade During Active Surveillance for Prostate Cancer. <i>European Urology Open Science</i> , 2022, 37, 113-119.	0.2	10
9	Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillance. <i>Cancer Medicine</i> , 2022, , .	1.3	3
10	Newly Diagnosed High-Risk Prostate Cancer in an Era of Rapidly Evolving New Imaging: How Do We Treat?. <i>Journal of Clinical Oncology</i> , 2021, 39, 13-16.	0.8	9
11	Response to Neoadjuvant Chemotherapy and Survival in Micropapillary Urothelial Carcinoma: Data From a Tertiary Referral Center and the Surveillance, Epidemiology, and End Results (SEER) Program. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 144-154.	0.9	13
12	Multiple Tissue Biomarkers Independently and Additively Predict Prostate Cancer Pathology Outcomes. <i>European Urology</i> , 2021, 79, 141-149.	0.9	4
13	Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer. <i>Prostate</i> , 2021, 81, 418-426.	1.2	8
14	Social and Clinical Correlates of Neoadjuvant Chemotherapy in Medicare Beneficiaries With Muscle Invasive Bladder Cancer From 2004-2015. <i>Urology</i> , 2021, 149, 154-160.	0.5	4
15	RNA Splicing Factors SRRM3 and SRRM4 Distinguish Molecular Phenotypes of Castration-Resistant Neuroendocrine Prostate Cancer. <i>Cancer Research</i> , 2021, 81, 4736-4750.	0.4	18
16	Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort. <i>Journal of Urology</i> , 2021, 206, 1147-1156.	0.2	14
17	Reply by Authors. <i>Journal of Urology</i> , 2021, 206, 1156.	0.2	0
18	Patterns and timing of perioperative blood transfusion and association with outcomes after radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 496.e1-496.e8.	0.8	1

#	ARTICLE	IF	CITATIONS
19	A 25-year perspective on evaluation and understanding of biomarkers in urologic cancers. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 602-617.	0.8	3
20	Effect of Diagnostic Biopsy Practice Location on Grade/Volume Reclassification in Active Surveillance for Prostate Cancer: A Multicenter Analysis from the Canary PASS Cohort. <i>Urology Practice</i> , 2021, 8, 576-582.	0.2	1
21	25-year perspective on prostate cancer: Conquering frontiers and understanding tumor biology. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 521-527.	0.8	3
22	Prognostic Genomic Biomarkers in Patients With Localized Prostate Cancer. <i>JAMA Oncology</i> , 2021, 7, 59.	3.4	3
23	The development and comparative effectiveness of a patient-centered prostate biopsy report: a prospective, randomized study. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 144-150.	2.0	9
24	Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 295-302.	2.0	30
25	Prostate cancer mortality and metastasis under different biopsy frequencies in North American active surveillance cohorts. <i>Cancer</i> , 2020, 126, 583-592.	2.0	9
26	Optimizing the management of castration-resistant prostate cancer patients: A practical guide for clinicians. <i>Prostate</i> , 2020, 80, 1159-1176.	1.2	11
27	Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk Stability. <i>JAMA Oncology</i> , 2020, 6, e203187.	3.4	30
28	17-Gene Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study (PASS) Cohort. <i>Journal of Clinical Oncology</i> , 2020, 38, 1549-1557.	0.8	48
29	Active Surveillance for Prostate Cancer: A 2020 Vision. <i>European Urology</i> , 2020, 77, 687-688.	0.9	2
30	EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study). <i>European Urology</i> , 2019, 76, 790-813.	0.9	151
31	Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS). <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 438-445.	2.0	22
32	The State of the Science on Prostate Cancer Biomarkers: The San Francisco Consensus Statement. <i>European Urology</i> , 2019, 76, 268-272.	0.9	28
33	Pathologic Nodal Involvement in Patients With Penile Cancer With Cavernosal Versus Spongiosal Involvement. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e156-e161.	0.9	8
34	Ferroptosis as a Novel Therapeutic Target for Friedreich's Ataxia. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 369, 47-54.	1.3	93
35	Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO and AUA Evidence-Based Guideline. <i>Journal of Urology</i> , 2019, 201, 528-534.	0.2	57
36	Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. <i>Journal of Clinical Investigation</i> , 2019, 129, 4492-4505.	3.9	250

#	ARTICLE	IF	CITATIONS
37	Validating the total illness burden index for prostate cancer (TIBI-CaP) in men with castration-resistant prostate cancer: data from TRUMPET. <i>Future Oncology</i> , 2018, 14, 527-536.	1.1	0
38	Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study. <i>European Urology</i> , 2018, 73, 706-712.	0.9	17
39	Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes. <i>European Urology</i> , 2018, 74, 211-217.	0.9	30
40	Updates in the Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers. <i>European Urology</i> , 2018, 73, 560-569.	0.9	401
41	Disparities in Access and Regionalization of Care in Testicular Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e785-e793.	0.9	32
42	A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer. <i>European Urology</i> , 2018, 73, 156-165.	0.9	55
43	Is there a benefit to adjuvant radiation in stage III penile cancer after lymph node dissection? Findings from the National Cancer Database. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 92.e11-92.e16.	0.8	18
44	Genomic Markers in Prostate Cancer Decision Making. <i>European Urology</i> , 2018, 73, 572-582.	0.9	201
45	Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. <i>Journal of Clinical Oncology</i> , 2018, 36, 414-424.	0.8	155
46	Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. <i>Journal of Clinical Oncology</i> , 2018, 36, 1498-1504.	0.8	34
47	Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO, and AUA Evidence-Based Guideline. <i>Practical Radiation Oncology</i> , 2018, 8, 354-360.	1.1	151
48	Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline. <i>Journal of Urology</i> , 2018, , .	0.2	16
49	Reply to Runqiang Yuan's Letter to the Editor re: James T. Kearns, Anna V. Faino, Lisa F. Newcomb, et al. Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study. <i>Eur Urol</i> 2018;73:706-712. <i>European Urology</i> , 2018, 74, e151.	0.9	0
50	Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts. <i>Annals of Internal Medicine</i> , 2018, 168, 1.	2.0	33
51	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. <i>Nature Genetics</i> , 2018, 50, 928-936.	9.4	652
52	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. <i>Nature Communications</i> , 2018, 9, 2256.	5.8	88
53	Timing of Adverse Prostate Cancer Reclassification on First Surveillance Biopsy: Results from the Canary Prostate Cancer Active Surveillance Study. <i>Journal of Urology</i> , 2017, 197, 1026-1033.	0.2	13
54	Gene expression panel predicts metastatic-lethal prostate cancer outcomes in men diagnosed with clinically localized prostate cancer. <i>Molecular Oncology</i> , 2017, 11, 140-150.	2.1	24

#	ARTICLE	IF	CITATIONS
55	Prostate cancer – major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. <i>Ca-A Cancer Journal for Clinicians</i> , 2017, 67, 245-253.	157.7	245
56	Role of radical prostatectomy in metastatic prostate cancer: A review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 125-134.	0.8	26
57	Decipher test impacts decision making among patients considering adjuvant and salvage treatment after radical prostatectomy: Interim results from the Multicenter Prospective PRO–IMPACT study. <i>Cancer</i> , 2017, 123, 2850-2859.	2.0	66
58	Neoadjuvant Enzalutamide Prior to Prostatectomy. <i>Clinical Cancer Research</i> , 2017, 23, 2169-2176.	3.2	80
59	Prostate Cancer Screening in a New Era of Genetics. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 625-628.	0.9	24
60	Independent Validation of the American Joint Committee on Cancer 8th Edition Prostate Cancer Staging Classification. <i>Journal of Urology</i> , 2017, 198, 1286-1294.	0.2	24
61	Do all men with pathological Gleason score 8–10 prostate cancer have poor outcomes? Results from the <sc>SEARCH</sc> database. <i>BJU International</i> , 2016, 118, 250-257.	1.3	12
62	Epigenetic signature of Gleason score and prostate cancer recurrence after radical prostatectomy. <i>Clinical Epigenetics</i> , 2016, 8, 97.	1.8	34
63	Predictors of Nodal Upstaging in Clinical Node Negative Patients With Penile Carcinoma: A National Cancer Database Analysis. <i>Urology</i> , 2016, 96, 29-34.	0.5	26
64	Prostate tumor DNA methylation is associated with cigarette smoking and adverse prostate cancer outcomes. <i>Cancer</i> , 2016, 122, 2168-2177.	2.0	47
65	PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer. <i>European Urology Focus</i> , 2016, 2, 180-188.	1.6	60
66	Extreme Gleason Upgrading From Biopsy to Radical Prostatectomy: A Population-based Analysis. <i>Urology</i> , 2016, 96, 148-155.	0.5	12
67	Stable Intraprostatic Dihydrotestosterone in Healthy Medically Castrate Men Treated With Exogenous Testosterone. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 2937-2944.	1.8	21
68	Characterizing the Morbidity of Postchemotherapy Retroperitoneal Lymph Node Dissection for Testis Cancer in a National Cohort of Privately Insured Patients. <i>Urology</i> , 2016, 91, 70-76.	0.5	16
69	Expression of cell cycle-regulated genes and prostate cancer prognosis in a population-based cohort. <i>Prostate</i> , 2015, 75, 1354-1362.	1.2	16
70	A multicenter study shows <i>PTEN</i> deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer. <i>Prostate</i> , 2015, 75, 1206-1215.	1.2	55
71	Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canary–Early Detection Research Network Active Surveillance Biopsy Risk Calculator. <i>European Urology</i> , 2015, 68, 1083-1088.	0.9	48
72	Measures of survival benefit in cancer drug development and their limitations. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 122-127.	0.8	4

#	ARTICLE	IF	CITATIONS
73	Preface. Urologic Clinics of North America, 2015, 42, xvii.	0.8	0
74	Cystic renal cell carcinoma carries an excellent prognosis regardless of tumor size. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 505.e9-505.e13.	0.8	46
75	Trends in Metastatic Kidney Cancer Survival From the Cytokine to the Targeted Therapy Era. Urology, 2015, 86, 262-268.	0.5	31
76	Can Urinary PCA3 Supplement PSA in the Early Detection of Prostate Cancer?. Journal of Clinical Oncology, 2014, 32, 4066-4072.	0.8	234
77	Readability of urologic pathology reports: The need for patient-centered approaches. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1091-1094.	0.8	18
78	Urinary TMPRSS2:ERG and PCA3 in an Active Surveillance Cohort: Results from a Baseline Analysis in the Canary Prostate Active Surveillance Study. Clinical Cancer Research, 2013, 19, 2442-2450.	3.2	132
79	The changing landscape of urologic oncology: Initiating systemic therapies, interventional skills, and clinical trials. Urologic Oncology: Seminars and Original Investigations, 2012, 30, S1.	0.8	1
80	Treatment and survival outcomes in young men diagnosed with prostate cancer. Cancer, 2009, 115, 2863-2871.	2.0	145
81	Beyond PSA: Utility of novel tumor markers in the setting of elevated PSA. Urologic Oncology: Seminars and Original Investigations, 2009, 27, 315-321.	0.8	22
82	Editorial Comment. Journal of Urology, 2009, 182, 2720-2720.	0.2	0
83	Does RPLND improve outcomes in men with intermediate-risk and high-risk germ cell tumors?. Nature Reviews Urology, 2007, 4, 654-655.	1.4	0
84	Is prediagnosis PSA velocity predictive of the risk of death from prostate cancer following radical prostatectomy?. Nature Reviews Urology, 2004, 1, 66-67.	1.4	0
85	The Role of Cyclooxygenase-2 Inhibition for the Prevention and Treatment of Prostate Carcinoma. Clinical Prostate Cancer, 2003, 2, 119-126.	2.1	34
86	Impact of Prostate Health Index Results for Prediction of Biopsy Grade Reclassification During Active Surveillance. Journal of Urology, 0, , .	0.2	1